Onkure Therapeutics Inc OKUR.OQ OKUR.O is expected to show no change in quarterly revenue when it reports results on May 5 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Onkure Therapeutics Inc is for a loss of $1.46 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Onkure Therapeutics Inc is $32.00, above its last closing price of $2.50.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.74 | -1.37 | Missed | -85.1 | |
Sep. 30 2024 | -1.03 | -1.03 | -1.10 | Missed | -6.8 |
Jun. 30 2024 | -1.00 | -1.60 | Missed | -60 | |
Mar. 31 2024 | -4.63 | -4.37 | -2.50 | Beat | 42.7 |
Dec. 31 2023 | -5.57 | -5.78 | -7.10 | Missed | -22.9 |
Sep. 30 2023 | -5.66 | -5.71 | -5.70 | Beat | 0.3 |
Jun. 30 2023 | -5.02 | -5.17 | -6.50 | Missed | -25.8 |
Mar. 31 2023 | -5.93 | -6.04 | -6.00 | Beat | 0.7 |
This summary was machine generated May 2 at 13:24 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。